Merck: takes over Velosbio for 2.75 billion dollars
(CercleFinance.com) - The US pharmaceutical giant Merck announced on Thursday that it has reached an agreement to acquire VelosBio for 2.
75 billion dollars in cash.
VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1..
Its most advanced project, VLS-101, has been in phase 2 clinical trials since last year for the treatment of solid tumours such as lung and breast cancer.
The deal is set to be closed by the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
75 billion dollars in cash.
VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1..
Its most advanced project, VLS-101, has been in phase 2 clinical trials since last year for the treatment of solid tumours such as lung and breast cancer.
The deal is set to be closed by the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.